What is PCVX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 10.62B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PCVX?

P/E (TTM) is n/a and 52-week range is $39.87 to $90.75 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PCVX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PCVX?

The company profile lists net income (TTM) near $-1.10B, EPS (TTM) near $-7.64 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Vaxcyte Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Carlos, California, US, 144.4M shares outstanding, ISIN US92243G1085 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Vaxcyte Inc

$PCVX

Health Care · Biotechnology

IR Run Scenarios

$71.38

+9.79%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. The company is headquartered in San Carlos, California and currently employs 507 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.

Employees

507

Website

vaxcyte.com/

IPO

2020-06-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)